Pharma Doubles Down on R&D Amid Global Headwinds, Eyes Nearly $340 Billion in Investment by 2030 Despite formidable political and economic challenges ranging from inflation and rising operational costs to…
AskBio Publishes Complete Phase 1b Trial Results of AB-1005 Gene Therapy for Parkinson’s Disease in Leading Neurology Journal Asklepios BioPharmaceutical, Inc. (AskBio), a pioneering gene therapy company that operates as…
Biogen and City Therapeutics Forge Strategic Partnership to Pioneer Next-Generation RNAi-Based Therapies Targeting Central Nervous System Diseases Biogen,a global leader in neuroscience and neurodegenerative disease research, and City Therapeutics, Inc.,…
Takeda and Nature Open Applications for 2026 Innovators in Science Award to Celebrate Emerging Scientific Talent Takeda Pharmaceutical Company Limited has officially opened the application window for its prestigious Innovators…
Novartis Launches Tender Offer to Acquire Regulus Therapeutics in $7 Per Share Deal, with Potential Bonus Payout Linked to Regulatory Milestone In a strategic move that underscores its continued investment…
AstraZeneca’s Imfinzi Gains CHMP Backing as First Perioperative Immunotherapy for Muscle-Invasive Bladder Cancer in the EU AstraZeneca has announced a significant regulatory milestone for its cancer immunotherapy, Imfinzi (durvalumab), with…
AbbVie Highlights Expanding Oncology Pipeline at ASCO 2025 with New Data Across Challenging Solid Tumors and Blood Cancers AbbVie has announced a significant presence at the upcoming 2025 American Society…
Eli Lilly to Acquire SiteOne Therapeutics in $1 Billion Deal to Advance Non-Opioid Pain Therapy In a strategic move aimed at strengthening its neuroscience and pain management portfolio, Eli Lilly…
Lupin and SteinCares Forge Strategic License and Supply Agreement to Commercialize Ranibizumab Biosimilar Across Latin America Global pharmaceutical leader Lupin Limited (Lupin) has officially announced the signing of a significant…
WHO Launches Landmark Guideline to Bridge Global Gaps in Access to Controlled Medicines In a bold step toward improving global health equity, the World Health Organization (WHO) unveiled a new…
Eisai’s Lemborexant (DAYVIGO®) Receives Regulatory Approval in China for the Treatment of Insomnia Eisai Co., Ltd., a leading global pharmaceutical company headquartered in Tokyo and led by CEO Haruo Naito,…
Partnering for Progress: How Astellas and the Pompe Disease Community Are Shaping the Future Together Pompe disease is a rare, inherited, and progressively debilitating disorder that profoundly affects the lives…